Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.53 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.52 |
| ▸ | AHR | P35869 | 3/20 | 0.51 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.51 |
| ▸ | CMA1 | P23946 | 2/20 | 0.50 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.49 |
| ▸ | TDP2 | O95551 | 5/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3573876 | 0.88 | SMYD3 (0.56) | SMYD3CRBNAHRPDK2CMA1 | |
| SCHEMBL3255662 | 0.88 | SMYD3 (0.53) | SMYD3AHRPDK2TDP2ATM | |
| SCHEMBL3581639 | 0.87 | TDP2 (0.55) | SMYD3CRBNAHRPDK2CMA1 | |
| SCHEMBL3573881 | 0.86 | SMYD3 (0.55) | SMYD3CRBNAHRPDK2CMA1 | |
| SCHEMBL3578248 | 0.85 | SMYD3 (0.52) | SMYD3CRBNAHRPDK2CMA1 | |
| SCHEMBL29713338 | 0.83 | TDP2 (0.66) | SMYD3CRBNAHRPDK2CMA1 | |
| SCHEMBL398818 | 0.83 | TDP2 (0.66) | SMYD3CRBNAHRPDK2CMA1 | |
| SCHEMBL3581850 | 0.82 | CRBN (0.45) | SMYD3CRBN | |
| SCHEMBL4874148 | 0.81 | SMYD3 (0.51) | SMYD3CRBNAHRPDK2CMA1 | |
| SCHEMBL4874161 | 0.81 | SMYD3 (0.51) | SMYD3CRBNAHRPDK2CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9789111-B2 | Casein kinase 1δ (CK 1δ) inhibitors | ELECTROPHORETICS LIMITED (GB) | 2017-10-17 | — | — | US | disclosed |
| US-9789111-B2 | Casein kinase 1δ (CK 1δ) inhibitors | ELECTROPHORETICS LIMITED (GB) | 2017-10-17 | — | — | US | disclosed |
| US-9763947-B2 | Casein kinase 1delta (CK1delta) inhibitors | ELECTROPHORETICS LIMITED (GB) | 2017-09-19 | — | — | US | disclosed |
| US-9763947-B2 | Casein kinase 1delta (CK1delta) inhibitors | ELECTROPHORETICS LIMITED (GB) | 2017-09-19 | — | — | US | disclosed |
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | ELECTROPHORETICS LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-20160058745-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | ELECTROPHORETICS LIMITED (GB) | 2016-03-03 | — | — | US | disclosed |
| US-20160058745-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | ELECTROPHORETICS LIMITED (GB) | 2016-03-03 | — | — | US | disclosed |
| EP-2651404-B1 | CASEIN KINASE 1DELTA (CK1DELTA) INHIBITORS | ELECTROPHORETICS LTD (GB) | 2015-10-14 | — | — | EP | disclosed |
| US-20150209368-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | ELECTROPHORETICS LIMITED (GB) | 2015-07-30 | — | — | US | disclosed |
| US-20150209368-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | ELECTROPHORETICS LIMITED (GB) | 2015-07-30 | — | — | US | disclosed |
| WO-1996023770-A1 | PROCESS FOR PREPARING 2-OXINDOLES AND N-HYDROXY-2-OXINDOLES | CATALYTICA, INC. (US) | 1996-08-08 | — | — | WO | disclosed |
| EP-0181136-B1 | OXINDOLE ANTIINFLAMMATORY AGENTS | PFIZER INC. (US) | 1992-03-25 | — | — | EP | disclosed |
| EP-0208510-B1 | 1-SUBSTITUTED OXINDOLE-3-CARBOXAMINES AS ANTIINFLAMMATORY AND ANALGESIC AGENTS | PFIZER INC. (US) | 1991-09-11 | — | — | EP | disclosed |
| US-4791129-A | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS | PFIZER INC. (US) | 1988-12-13 | — | — | US | disclosed |
| US-4725616-A | ANTIARTHRITIC AGENTS | PFIZER INC. (US) | 1988-02-16 | — | — | US | disclosed |
| US-4686224-A | Oxindole antiinflammatory agents | PFIZER INC. (US) | 1987-08-11 | — | — | US | disclosed |
| US-4644005-A | ANTIARTHRITIC AGENTS | PFIZER INC. (US) | 1987-02-17 | — | — | US | disclosed |
| EP-0208510-A2 | 1-Substituted oxindole-3-carboxamines as antiinflammatory and analgesic agents | PFIZER INC. (US) | 1987-01-14 | — | — | EP | disclosed |
| CN-86105309-A | Oxindole-3-carbonyl amines the compound that replaces as the 1-of anti-inflammatory and anodyne | — | 1987-01-14 | — | — | CN | disclosed |
| EP-0181136-A2 | Oxindole antiinflammatory agents | PFIZER INC. (US) | 1986-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209368-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | CSNK1A1, CSNK1G1, CSNK1D | SMYD3 3568/4885CRBN 400/4885AHR 4457/4885 |
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | CSNK1G1, CSNK1A1, CSNK1D | SMYD3 3473/4885CRBN 341/4885AHR 4555/4885 |
| US-20160058745-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | CSNK1A1, CSNK1G1, CSNK1D | SMYD3 3568/4885CRBN 400/4885AHR 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.